Why Resting Heart Rate Rises on Semaglutide or Tirzepatide and Whether It Is Dangerous

If your resting pulse reads a few beats higher since starting semaglutide or tirzepatide, that matches what trials report. Animal work points to a direct effect on your heart's natural pacemaker. That small rise came with lower blood pressure and no higher cardiovascular risk signal in diabetes trials, with caution still noted for advanced weak-pump heart failure.

How do these drugs raise pulse?

Your pulse starts in the sinus node, a small patch of pacemaker cells in the upper heart that sets the pace for each beat. In female pigs, researchers found GLP-1 receptors on those pacemaker cells, and GLP-1 made the cells fire sooner by changing how they move calcium inside the cell pig sinus-node study.

The faster pace stayed even after nerve signals were cut, adrenaline signals were blocked, and a pulse-slowing drug that works through a different channel was given. That result points to a direct pacemaker effect pig sinus-node study. This was animal work, so it shows a possible path in people that researchers are still confirming. Pilot studies in Cambridge plan to test in people whether these drugs change blood vessel responses apart from weight loss DECODE pilots.

How big is the rise, and what happens to blood pressure?

A review of 24-hour recordings in 1,112 people on treatment found the size tracks how long the drug stays active 24-hour heart rate review. Short-acting drugs raised average pulse by 1 to 3 beats per minute for a few hours before it fell back. Long-acting drugs raised it day and night, by 3 to 4 beats per minute for dulaglutide and weekly exenatide and by 6 to 10 beats per minute for liraglutide and albiglutide 24-hour heart rate review.

Semaglutide and tirzepatide stay active all week, so a steady rise of a few beats fits that long-acting pattern. In SURMOUNT-1 with 2,539 people with obesity, a cardiologist summary noted tirzepatide lowered systolic and diastolic blood pressure in clinic readings while heart rate rose, as expected with this drug class SURMOUNT-1 heart summary.

Is a few extra beats dangerous?

In type 2 diabetes trials, that pulse rise did not bring higher cardiovascular risk 24-hour heart rate review. For heart failure, the type matters. HFpEF means the heart still pumps but has grown stiff and struggles to fill. HFrEF means the pumping strength itself is weak.

In SUMMIT in people with obesity-related HFpEF, those on tirzepatide had fewer worsening heart-failure events, healthier heart size and shape on scans, and lower blood markers of heart stress than those on placebo tirzepatide heart failure review. Data in HFrEF remain limited, and reviewers advise caution there because rapid weight loss can strain advanced weak-pump failure tirzepatide heart failure review. If you live with weak-pump failure, bring a log of resting pulse with blood pressure to your cardiology visit so the plan can reflect both numbers.